Blockade of PDGFRβ circumvents resistance to MEK-JAK inhibition via intratumoral CD8+ T-cells infiltration in triple-negative breast cancer

[1]  S. Lakhani,et al.  CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer , 2018, EMBO molecular medicine.

[2]  E. Winer,et al.  Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer , 2018, npj Breast Cancer.

[3]  C. Pellet-Many,et al.  Receptor Tyrosine Kinase Ubiquitination and De-Ubiquitination in Signal Transduction and Receptor Trafficking , 2018, Cells.

[4]  K. Pietras,et al.  The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence , 2018, Breast Cancer Research and Treatment.

[5]  D. Fremont,et al.  Natural Killer Cells Control Tumor Growth by Sensing a Growth Factor , 2017, Cell.

[6]  H. Clevers,et al.  Cancer stem cells revisited , 2017, Nature Medicine.

[7]  Franco Locatelli,et al.  Imatinib and Nilotinib Off-Target Effects on Human NK Cells, Monocytes, and M2 Macrophages , 2017, The Journal of Immunology.

[8]  L. Qu,et al.  At the crossroads of cancer stem cells and targeted therapy resistance. , 2017, Cancer letters.

[9]  M. Ragan,et al.  The metastasis suppressor RARRES3 as an endogenous inhibitor of the immunoproteasome expression in breast cancer cells , 2017, Scientific Reports.

[10]  C. Gong,et al.  Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast Cancer* , 2016, The Journal of Biological Chemistry.

[11]  L. Helman,et al.  The Role of PDGFR-β Activation in Acquired Resistance to IGF-1R Blockade in Preclinical Models of Rhabdomyosarcoma1 , 2016, Translational oncology.

[12]  Deborah S. Barkauskas,et al.  Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis. , 2016, Cancer research.

[13]  N. Hynes,et al.  Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models , 2016, Nature Communications.

[14]  R. Yelensky,et al.  Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence , 2016, Science Translational Medicine.

[15]  M. Belvin,et al.  MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade. , 2016, Immunity.

[16]  Dhaval Patel,et al.  Understanding the functional impact of copy number alterations in breast cancer using a network modeling approach. , 2016, Molecular bioSystems.

[17]  I. Fernández,et al.  Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting , 2016, Clinical Medicine Insights. Oncology.

[18]  Sriganesh Srihari,et al.  Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease. , 2015, Trends in pharmacological sciences.

[19]  Jong-In Park,et al.  MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms. , 2015, Seminars in oncology.

[20]  T. Kondo,et al.  AG490, a Jak2 inhibitor, suppressed the progression of murine ovarian cancer. , 2015, European journal of pharmacology.

[21]  H. Sasano,et al.  Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study , 2015, Breast Cancer Research.

[22]  J. Koo,et al.  Differential expression of cancer-associated fibroblast-related proteins according to molecular subtype and stromal histology in breast cancer , 2015, Breast Cancer Research and Treatment.

[23]  Yan Zhou,et al.  Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth , 2015, Molecular Cancer Therapeutics.

[24]  T. Nielsen,et al.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  Guojun Wu,et al.  PDGFRα and β play critical roles in mediating Foxq1-driven breast cancer stemness and chemoresistance. , 2015, Cancer research.

[26]  Ki-Chun Yoo,et al.  Activation of KRAS promotes the mesenchymal features of basal-type breast cancer , 2015, Experimental & Molecular Medicine.

[27]  F M Blows,et al.  Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  P. Johnston,et al.  ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer. , 2014, Cell reports.

[29]  E. Ranheim,et al.  Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm. , 2014, The Journal of clinical investigation.

[30]  C. Gialeli,et al.  PDGF/PDGFR signaling and targeting in cancer growth and progression: Focus on tumor microenvironment and cancer-associated fibroblasts. , 2014, Current pharmaceutical design.

[31]  Justin M Balko,et al.  Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer. , 2014, Discovery medicine.

[32]  A. Vargas,et al.  Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer , 2014, Oncotarget.

[33]  R. Bernards,et al.  Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma , 2014, Nature.

[34]  R. Yelensky,et al.  Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. , 2014, Cancer discovery.

[35]  C. Heldin,et al.  Targeting the PDGF signaling pathway in tumor treatment , 2013, Cell Communication and Signaling.

[36]  P. Johnston,et al.  Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.

[37]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[38]  Michal Sheffer,et al.  Pathway-based personalized analysis of cancer , 2013, Proceedings of the National Academy of Sciences.

[39]  Ivan Babic,et al.  De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. , 2013, Cancer discovery.

[40]  H. Brinkhaus,et al.  JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. , 2012, Cancer cell.

[41]  Sridhar Ramaswamy,et al.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..

[42]  G. Mills,et al.  Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance , 2012, Nature Medicine.

[43]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[44]  Jian Jin,et al.  Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer , 2012, Cell.

[45]  Jeremy S Logue,et al.  Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy. , 2012, Genes & development.

[46]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[47]  G. Federici,et al.  Platinum-(IV)-derivative satraplatin induced G2/M cell cycle perturbation via p53-p21waf1/cip1-independent pathway in human colorectal cancer cells , 2011, Acta Pharmacologica Sinica.

[48]  Mithat Gönen,et al.  The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. , 2011, The Journal of clinical investigation.

[49]  Z. Szallasi,et al.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.

[50]  E. Alba,et al.  Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer , 2010, BMC Cancer.

[51]  L. Ellis,et al.  Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology , 2009, Clinical Cancer Research.

[52]  Wei Zhou,et al.  In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models , 2009, Clinical Cancer Research.

[53]  J. Bergh,et al.  Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. , 2009, The American journal of pathology.

[54]  A. Richardson,et al.  Reciprocal Effects of STAT5 and STAT3 in Breast Cancer , 2009, Molecular Cancer Research.

[55]  Johanna Andrae,et al.  Role of platelet-derived growth factors in physiology and medicine. , 2008, Genes & development.

[56]  M. Rojewski,et al.  Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling , 2008, Journal of cellular and molecular medicine.

[57]  C. Cordon-Cardo,et al.  Autocrine PDGFR signaling promotes mammary cancer metastasis. , 2006, The Journal of clinical investigation.

[58]  J. Soulier,et al.  Imatinib mesylate minimally affects bcr‐abl+ and normal monocyte‐derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell‐T cell activation , 2006, Journal of leukocyte biology.

[59]  C. Restall,et al.  Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix. , 2005, Molecular cancer research : MCR.

[60]  Zhixiang Wang,et al.  Platelet-derived Growth Factor Receptor-mediated Signal Transduction from Endosomes* , 2004, Journal of Biological Chemistry.

[61]  Jayanta Debnath,et al.  Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. , 2003, Methods.

[62]  B. Barre,et al.  Opposite Regulation of Myc and p21 waf1 Transcription by STAT3 Proteins* , 2003, The Journal of Biological Chemistry.

[63]  T. Yeatman,et al.  Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[64]  B. Druker,et al.  The tyrosine kinase regulator Cbl enhances the ubiquitination and degradation of the platelet-derived growth factor receptor alpha. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[65]  S. Ōmura,et al.  Degradation Process of Ligand-stimulated Platelet-derived Growth Factor β -Receptor Involves Ubiquitin-Proteasome Proteolytic Pathway * , 1995, The Journal of Biological Chemistry.

[66]  Mei Wang,et al.  PDGF signaling in cancer progression , 2017 .

[67]  Carsten Denkert,et al.  Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  John D. Watson,et al.  Promoter-binding and repression of PDGFRB by c-Myc are separable activities. , 2004, Nucleic acids research.